The drugmakers said they will combine technology Sanofi has used to make the flu vaccine, called FluBlok, with GlaxoSmithKline’s adjuvant, an additive that increases the effectiveness of vaccines and allows them to be mass-produced, according to The Hill.
The drugmakers got funding from the Biomedical Advanced Research and Development Authority, an office within HHS, and said they plan to reach out to other governments for more funding.
The companies said they are hoping the vaccine can be tested on humans in the second half of this year and receive regulatory approval by the second half of 2021.
Read the full news release here.
More articles on pharmacy:
Death penalty states hoarding drugs needed to ventilate COVID-19 patients
UnitedHealthcare to pay Ohio pharmacists as medical providers
Purdue University grants early graduation to 144 pharmacy students
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
